Biologic Agents in the Treatment of Urticaria
Current Allergy and Asthma Reports, 07/06/2012
Kaplan AP – Omalizumab is currently marketed for the treatment of severe allergic asthma. Case reports suggest efficacy in difficult cases of physical urticaria, but no controlled trails have been done. Other agents require further evaluation for possible efficacy in the treatment of chronic spontaneous urticaria, including antibody to CD20, a B–lymphocyte cell surface marker, anti–TNFα, and anti–Interleukin 1.